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Abstract
Background: The impact of the pneumococcal conjugate vaccine (PCV-7) on antibiotic resistance among pneumococcal
strains causing invasive pneumococcal disease (IPD) has varied in different locales in the United States. We assessed trends
in IPD including trends for IPD caused by penicillin non-susceptible strains before and after licensure of PCV-7 and the
impact of the 2008 susceptibility breakpoints for penicillin on the epidemiology of resistance.
Methodology/Principal Findings: We performed a retrospective review of IPD cases at Morgan Stanley Children’s Hospital
of NewYork-Presbyterian, Columbia University Medical Center. Subjects were #18 years of age with Streptococcus
pneumoniae isolated from sterile body sites from January 1995–December 2006. The rate of IPD from 1995–1999 versus
2002–2006 significantly decreased from 4.1 (CI95 3.4, 4.8) to 1.7 (CI95 1.3, 2.2) per 1,000 admissions. Using the breakpoints in
place during the study period, the proportion of penicillin non-susceptible strains increased from 27% to 49% in the pre- vs.
post-PCV-7 era, respectively (p=0.001), although the rate of IPD caused by non-susceptible strains did not change from
1995–1999 (1.1 per 1,000 admissions, CI95 0.8, 1.5) when compared with 2002–2006 (0.8 per 1,000 admissions, CI95 0.6, 1.2).
In the multivariate logistic regression model controlling for the effects of age, strains causing IPD in the post-PCV-7 era were
significantly more likely to be penicillin non-susceptible compared with strains in the pre-PCV-7 era (OR 2.46, CI95 1.37, 4.40).
However, using the 2008 breakpoints for penicillin, only 8% of strains were non-susceptible in the post-PCV-7 era.
Conclusions/Significance: To date, there are few reports that document an increase in the relative proportion of penicillin
non-susceptible strains of pneumococci causing IPD following the introduction of PCV-7. Active surveillance of
pneumococcal serotypes and antibiotic resistance using the new penicillin breakpoints is imperative to assess potential
changes in the epidemiology of IPD.
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Introduction
Invasive pneumococcal disease (IPD) caused by strains non-
susceptible to penicillin became increasingly prevalent during the
mid-1990’s. In 1998, the Center for Disease Control and Prevention
reported that 24% of strains associated with IPD were non-
susceptible to penicillin and that serotypes 6B, 9V, 14, 19F, and 23F
accounted for 78% of penicillin non-susceptible strains [1]. In 2000,
the heptavalent pneumococcal conjugate vaccine (PCV-7) was
approved by the FDA to reduce the burden of pneumococcal
disease, and in August 2000, the American Academy of Pediatrics
recommended that all children younger than 2 years of age and
high-risk children 2–5 years of age receive PCV-7 [2]. By 2006, 87%
of American children 19–35 months of age had received 3 or more
doses of PCV-7 [3] and numerous studies have documented a
reduction in the incidence of IPD [4–6].
However, the impact of PCV-7 on the proportion of penicillin
non-susceptible strains causing IPD has varied [5,7–8]. Notably,
these studies did not assess changes in the rates of invasive disease
caused by such strains. In Utah, the proportion of penicillin non-
susceptible strains decreased from 34% in the pre-PCV-7 era to
22% in the post-PCV-7 era [5]. In Dallas, no change in penicillin
susceptibility was noted between 1999 and 2005 [7] and in
Philadelphia, a 14% relative increase in the proportion of
penicillin non-susceptible strains was observed following PCV-7
approval [8]. We assessed trends in hospital admissions for IPD
before and after licensure of PCV-7 at our children’s hospital in
New York City. We also examined the epidemiology of
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e5965antimicrobial susceptibility, including the impact of the 2008
susceptibility breakpoints for penicillin [9].
Methods
Study Design and Study Site
We reviewed cases of IPD admitted to the Morgan Stanley
Children’s Hospital of NewYork-Presbyterian, Columbia Univer-
sity Medical Center located in New York City from January 1,
1995 to December 31, 2006. The Institutional Review Board of
Columbia University approved this study with a waiver of
documentation of informed consent.
Study Subjects and Study Isolates
The electronic data warehouse was queried for patients #18
years of age with a positive culture for S. pneumoniae isolated from
blood, cerebrospinal fluid (CSF), pleural fluid, joint fluid, bone,
and/or abscesses during the study period. If more than one culture
from an individual patient was positive for S. pneumoniae, only the
first was included in the analysis, and if both blood and CSF
cultures were positive, the strain from CSF was included.
Antimicrobial Susceptibilities
Antimicrobial susceptibilities as determined by the Clinical
Laboratory and Standards Institute (formerly the National
Committee on Clinical Laboratory Standards) in use during the
study period [10] were compared to those introduced in 2008 [9].
During the study period, the breakpoints in use for penicillin for
CSF and non-CSF isolates were comparable: susceptible #0.06,
intermediate $0.1–1, and resistant $2 mg/ml. In 2008, the
breakpoints were changed for both CSF isolates: susceptible #0.06
and resistant $0.12 mg/ml and for non-CSF isolates: susceptible
#2, intermediate 4, and resistant $8 mg/ml. Breakpoints for 3
rd
generation cephalosporins did not change; CSF isolates: suscep-
tible #0.5, intermediate 1, and resistant $2 mg/ml and non-CSF
isolates: susceptible #1, intermediate 2, and resistant $4 mg/ml.
Statistical Analysis
Categorical variables were summarized as proportions. Pre-
(1995–2000) and post- (2001–2006) PCV-7 variables were
compared using the Chi-squared test and continuous variables
were compared using the two-sample t-test. Multivariate logistic
regression was used to estimate the rate change for penicillin
susceptibility between the pre- and post-PCV-7 eras, controlling
for age as a possible confounding variable. As PCV-7 was
introduced in August 2000, 2000–2001 were considered to be
transition years and thus the rate of IPD and the rate of IPD
caused by penicillin non-susceptible strains was compared from
1995–1999 versus 2002–2006.
Results
During the 12-year study period, 242 cases of IPD occurred of
which 169 (70%) cases occurred from 1995–2000. Overall,
bacteremia (n=215) and meningitis (n=17) were the most
common diagnoses, and 56% of IPD cases occurred in boys.
Figure 1. Invasive pneumococcal disease at a NYC Children’s Hospital, 1995–2006. The number of cases of invasive pneumococcal disease
(IPD) caused by penicillin resistant, intermediate, and susceptible strains of S. pneumoniae is shown (Left-hand Y axis). The rate of IPD per 1000
admissions and the rate of IPD caused by penicillin non-susceptible strains per 1000 admissions are shown (Right-hand Y-axis).
doi:10.1371/journal.pone.0005965.g001
Resistance Pre- and Post-PCV-7
PLoS ONE | www.plosone.org 2 June 2009 | Volume 4 | Issue 6 | e5965The rate of IPD from 1995–1999 vs. 2002–2006 significantly
decreased (p,0.001) from 4.1 (CI95 3.4, 4.8) to 1.7 (CI95 1.3, 2.2)
per 1,000 admissions as shown in the Figure 1.
Children with IPD were younger in the pre-PCV-7 era than
children in the post-PCV-7 era (mean age 2.8 versus 4.6 years,
respectively, p=0.001). In the pre-PCV-7 era, children #2 years
of age were less likely to be infected with non-susceptible strains
(breakpoints in use during the study period) than older children
(OR 0.4, CI95 0.2, 0.8, p=0.01) as 19 (20%) of 95 children #2
years of age versus 26 (37.7%) of 69 children .2 years of age were
infected with non-susceptible strains. In the post-PCV-7 era, there
was no association between age and non-susceptible strains as 15
(43%) of 35 children #2 years of age versus 21 (55%) of 38
children .2 years of age were infected with non-susceptible strains
(p=0.29).
As interpreted by the breakpoints in use during the study period,
the MIC50 (median MIC) for penicillin in the pre-PCV-7 era was
0.06 mg/ml and in the post-PCV-7 era was 0.094 mg/ml, while the
MIC90 (90
th percentile MIC) in the pre-PCV-7 era was 1.0 mg/ml
and in the post-PCV-7 era was 2.0 mg/ml. In the pre-PCV-7 era,
45 (27%) of 164 tested strains were non-susceptible to penicillin
(MIC $0.1 mg/ml) while in the post-PCV-7 era, 36 (49%) of 73
strains were non-susceptible (p=0.001). In the multivariate logistic
regression model controlling for the effects of age, strains of IPD in
the post-PCV-7 era were significantly more likely to be penicillin
non-susceptible than strains in the pre-PCV-7 era (OR 2.5, CI95
1.4, 4.4, p=0.003). However, the rate of IPD caused by non-
susceptible strains did not change from 1995–1999 (1.1 per 1,000
admissions, CI95 0.8, 1.5) when compared with 2002–2006 (0.8
per 1,000 admissions, CI95 0.6, 1.2).
As expected, the breakpoints introduced in 2008 changed the
epidemiology of penicillin resistance. A comparison of the
proportion of penicillin non-susceptible strains using the previous
and current breakpoints for non-CSF and CSF isolates from the
pre- and post-PCV-7 era is shown in Table 1. Among the 220
non-CSF isolates from the study period, the proportion of
penicillin-resistant strains would decrease from 10% (22/220)
using previous breakpoints to 1.4% (3/220) using current break-
points (p,0.001). Similarly, the proportion of intermediately
susceptible non-CSF isolates would decrease from 24% (53/220)
to 3% (6/220) [p,0.001]. In contrast, among the 17 CSF isolates
from the study period, the proportion of resistant strains would not
significantly change; there were 2 (12%) resistant strains using
previous breakpoints vs. 6 (35%) resistant strains using current
breakpoints (p=0.106). Thus, in the post-PCV-7 era, there were
only 4 non-CSF and 2 CSF isolates that were non-susceptible to
penicillin using current breakpoints.
There was no significant change in susceptibility to 3
rd
generation cephalosporin agents (p=0.66) in the pre- vs. post-
PCV-7 eras; only 3.0% (4/132 tested strains) and 1.4% (1/70
tested strains) were non-susceptible to these agents, respectively.
All tested strains (n=208) were susceptible to vancomycin during
the study period. In the post-PCV-7 era, all tested strains (n=67)
were susceptible to levofloxacin. In contrast, resistance to
erythromycin increased from 6.7% (7/105 tested strains) in the
pre-PCV-7 era to 29.6% (21/71 tested strains) in the post-PCV-7
era (p,0.001).
Discussion
In our patient population, the incidence of IPD before and
following PCV-7 licensure was similar to previous reports [4,5,7].
Prior studies have also documented an increase in the mean age of
patients with IPD in the post-PCV-7 era [4,5,7]. However, as our
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are not population-based and our findings may not be general-
izable to other clinical and geographic settings. Furthermore, we
could not assess the efficacy of PCV-7 vaccine on actual cases of
IPD.
To our knowledge, when compared with other studies
performed throughout the U.S. (Table 2), this is one of the few
reports to document an increase in the relative proportion of
penicillin non-susceptible strains following the introduction of
PCV-7. However, most previous reports have not addressed
changes in the rate of IPD caused by non-susceptible pneumo-
coccal strains and generally have not used the penicillin break-
points recently introduced by the CLSI [9]. As we have shown, use
of these new breakpoints would most likely decrease the
proportion of non-susceptible strains isolated from non-CSF
sources and increase the proportion of non-susceptible strains
isolated from the CSF. Furthermore, we demonstrated that
younger children were less likely to be infected with non-
susceptible strains in the pre-PCV-7 era. We speculate that the
shift to IPD in older children during the post-PCV-7 era could
have influenced the penicillin non-susceptibility profile between
the pre- and post-PCV-7 eras as older children could have had
more exposure to antibiotics and thus be more likely to be infected
with non-susceptible pneumococci.
While our findings may be due to pneumococcal serotype
replacement or emergence of a new serotype in the post-PCV-7
era, such as been shown in diverse locations in the U.S., [Table 2]
we were unable to assess this possibility because we did not
systematically study serotypes.
Monitoring the burden of IPD in the United States is needed to
continue to assess the efficacy of the PCV-7 vaccine as well as the
efficacy of newer, more extensive valent PCVs. Surveillance must
include the antimicrobial susceptibility and pneumococcal sero-
types associated with IPD. While our results suggest the continued
need for empiric treatment of penicillin non-susceptible strains,
particularly if meningitis is suspected, epidemiologic trends for
antimicrobial susceptibility should be studied with the new
penicillin breakpoints.
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